- Conditions
- Psychotic Disorder, Schizophreniform Disorder, Schizophrenia, Schizoaffective Disorder, Mood Disorders With Psychotic Features
- Interventions
- Olanzapine, Amantadine, Olanzapine and placebo
- Drug
- Lead sponsor
- University of North Carolina, Chapel Hill
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2009
- U.S. locations
- 1
- States / cities
- Chapel Hill, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1009–1032
of 1,738
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Tinnitus
- Interventions
- Sham Treatment: unimodal auditory stimulation, Active Treatment: Bimodal auditory-somatosensory stimulation
- Device
- Lead sponsor
- University of Michigan
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 35 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan
- Conditions
- Insomnia Disorder
- Interventions
- ACT-541468, Placebo
- Drug
- Lead sponsor
- Idorsia Pharmaceuticals Ltd.
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 5
- States / cities
- Brandon, Florida • Chicago, Illinois • Las Vegas, Nevada + 2 more
- Conditions
- Migraine, With or Without Aura
- Interventions
- Ubrogepant, Placebo-matching Ubrogepant
- Drug
- Lead sponsor
- Allergan
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1,686 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 109
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 91 more
- Conditions
- Healthy
- Interventions
- Placebo Administration first, Low Caffeine Administration first (1mg/kg body weight), High Caffeine Administration first (2mg/kg body weight)
- Drug
- Lead sponsor
- State University of New York at Buffalo
- Other
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 101 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Buffalo, New York
- Conditions
- Hypoxic Ischemic Encephalopathy
- Interventions
- Darbepoetin alfa, Placebo
- Drug
- Lead sponsor
- University of Utah
- Other
- Eligibility
- Up to 24 Hours
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 7
- States / cities
- Albuquerque, New Mexico • Nashville, Tennessee • Ogden, Utah + 3 more
- Conditions
- Infertility
- Interventions
- MENOPUR solution for injection in pre-filled pen, 1200 IU/1.92 mL, MENOPUR powder and solvent for solution for injection, 75 IU, Placebo (for MENOPUR solution for injection in pre-filled pen), Placebo (for MENOPUR powder and solvent for solution for injection)
- Drug · Other
- Lead sponsor
- Ferring Pharmaceuticals
- Industry
- Eligibility
- 18 Years to 42 Years · Female only
- Enrollment
- 405 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2021
- U.S. locations
- 20
- States / cities
- Tempe, Arizona • San Diego, California • Farmington, Connecticut + 17 more
- Conditions
- Oxidative Stress
- Interventions
- Placebo low dose, N Acetyl cysteine, 600mg (low dose), Proimmune 200 (FT061452) 3000mg low dose, Placebo (high dose), N Acetyl cysteine, 1200mg (high dose), FT061452, 6000mg high dose
- Drug
- Lead sponsor
- Charles Drew University of Medicine and Science
- Other
- Eligibility
- 30 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2010 – 2011
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Opioid Consumption, Postoperative
- Interventions
- Suzetrigine, Standard Care (in control arm)
- Drug
- Lead sponsor
- University of California, San Diego
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- La Jolla, California
- Conditions
- Obesity, Overweight, Cigarette Smoking
- Interventions
- semaglutide 2.4mg, Placebo, Nicotine Replacement Therapy (NRT, nicotine patch), Brief Smoking Cessation Counseling
- Drug · Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 197 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Austin, Texas • Houston, Texas
- Conditions
- Major Depressive Disorder
- Interventions
- duloxetine hydrochloride, placebo
- Drug
- Lead sponsor
- Eli Lilly and Company
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 370 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 23
- States / cities
- Pasadena, California • Sherman Oaks, California • Hamden, Connecticut + 20 more
- Conditions
- Diabetes Mellitus, Type 1
- Interventions
- Canagliflozin 100 mg, Canagliflozin 300 mg, Placebo
- Drug
- Lead sponsor
- Janssen Research & Development, LLC
- Industry
- Eligibility
- 25 Years to 65 Years
- Enrollment
- 352 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2015
- U.S. locations
- 46
- States / cities
- Little Rock, Arkansas • Concord, California • La Jolla, California + 43 more
- Conditions
- Acute Pain, Post Operative Pain, Pain
- Interventions
- MR-107A-02, Tramadol, Placebo, Bunionectomy
- Drug · Procedure
- Lead sponsor
- Viatris Specialty LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 410 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 15
- States / cities
- Sheffield, Alabama • Phoenix, Arizona • Anaheim, California + 12 more
- Conditions
- Restless Leg Syndrome
- Interventions
- incobotulinumtoxinA, Placebo
- Drug
- Lead sponsor
- Yale University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 24 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 1
- States / cities
- New Haven, Connecticut
- Conditions
- Chronic Limb Ischemia
- Interventions
- Temsirolimus, Saline
- Drug
- Lead sponsor
- Mercator MedSystems, Inc.
- Industry
- Eligibility
- 18 Years to 90 Years
- Enrollment
- 100 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Orange, California • Denver, Colorado + 5 more
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- Alogliptin Benzoate, Placebo
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 152 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 34
- States / cities
- Little Rock, Arkansas • Los Angeles, California • Palmdale, California + 31 more
- Conditions
- Obesity
- Interventions
- Behavioral Treatment, Placebo, Phentermine 15 MG
- Behavioral · Drug
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 21 Years to 70 Years
- Enrollment
- 147 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Mild Cognitive Impairment, Insomnia
- Interventions
- Multicomponent Behavioral Sleep Intervention for Insomnia, Active Control
- Behavioral
- Lead sponsor
- University of Pennsylvania
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Gastric Neoplasms, Gastroesophageal Junction Adenocarcinoma
- Interventions
- Pembrolizumab, Placebo, Cisplatin, 5-FU, Oxaliplatin, Capecitabine, S-1, Trastuzumab
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 738 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 23
- States / cities
- Los Angeles, California • Monterey, California • Orange, California + 19 more
- Conditions
- Herpes Zoster
- Interventions
- Herpes Zoster Vaccine 1437173A, Placebo vaccine (saline)
- Biological
- Lead sponsor
- GlaxoSmithKline
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2012
- U.S. locations
- 11
- States / cities
- Little Rock, Arkansas • Duarte, California • San Francisco, California + 8 more
- Conditions
- Pulmonary Hypertension, Bronchopulmonary Dysplasia
- Interventions
- inhaled nitric oxide, Placebo
- Drug
- Lead sponsor
- AdventHealth
- Other
- Eligibility
- 23 Weeks to 29 Weeks
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Orlando, Florida
- Conditions
- Helicobacter Pylori
- Interventions
- Bismuth quadruple therapy with optimized proton pump inhibitor (PPI), Bismuth quadruple therapy with standard proton pump inhibitor (PPI), Clarithromycin triple therapy with optimized proton pump inhibitor (PPI), Clarithromycin triple therapy with standard PPI, Standard bismuth quadruple therapy
- Drug
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 18 Years and older
- Enrollment
- 360 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2030
- U.S. locations
- 1
- States / cities
- San Diego, California
- Conditions
- Preeclampsia
- Interventions
- Recombinant human antithrombin (ATryn), Normal Saline 0.9%
- Biological · Other
- Lead sponsor
- rEVO Biologics
- Industry
- Eligibility
- 16 Years and older · Female only
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2016
- U.S. locations
- 23
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 19 more
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- Pembrolizumab, Normal saline solution, Carboplatin, Cisplatin, Etoposide
- Biological · Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 453 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2021
- U.S. locations
- 27
- States / cities
- Miami, Florida • Chicago, Illinois • Evanston, Illinois + 21 more